Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Thierry André, Kimmie Ng et al.|The Lancet Oncology|2023Cited by 244
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancerVivek Nimgaonkar, Eric A. Collisson, Viswesh Krishna et al.|Cell Reports Medicine|2023Cited by 19